These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 36598048

  • 1. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.
    Wang Y, Zhao C, Ma P, Jiang D.
    Cancer Control; 2023; 30():10732748221140289. PubMed ID: 36598048
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
    Tseng TH, Chiang SC, Hsu JC, Ko Y.
    PLoS One; 2024; 19(6):e0303294. PubMed ID: 38857244
    [Abstract] [Full Text] [Related]

  • 3. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
    Xia W, Wang SS, Hu H, Zhao FL, Xu F, Hong RX, Jiang KK, Yuan ZY, Shi YX, Zhao K, Huang JJ, Xue C, Bi XW, Lu QY, An X, Zhang JM.
    Zhonghua Zhong Liu Za Zhi; 2020 Oct 23; 42(10):861-867. PubMed ID: 33113628
    [Abstract] [Full Text] [Related]

  • 4. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C, Rayson D, Younis T.
    Support Care Cancer; 2016 Jan 23; 24(1):387-394. PubMed ID: 26081595
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.
    Pharmacoeconomics; 2012 Feb 01; 30(2):103-18. PubMed ID: 21967155
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1078-85. PubMed ID: 23873405
    [Abstract] [Full Text] [Related]

  • 7. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z, Doan QV, Malin J, Leonard R.
    Appl Health Econ Health Policy; 2009 Aug 07; 7(3):193-205. PubMed ID: 19799473
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH.
    Value Health; 2009 Aug 07; 12(2):217-25. PubMed ID: 18673353
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK, Wong WW, Trudeau ME, Chan KK.
    Breast Cancer Res Treat; 2015 Feb 07; 150(1):169-80. PubMed ID: 25694355
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.
    Wen TJ, Wen YW, Chien CR, Chiang SC, Hsu WW, Shen LJ, Hsiao FY.
    J Eval Clin Pract; 2017 Apr 07; 23(2):288-293. PubMed ID: 27491287
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb 07; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.
    Value Health; 2011 Jun 07; 14(4):465-74. PubMed ID: 21669371
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM.
    J Clin Oncol; 2012 Apr 01; 30(10):1064-71. PubMed ID: 22393098
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL, Chan K, Kurin M, Pasetka M, Kiss A, Sridhar SS, Warner E.
    Breast J; 2015 Apr 01; 21(6):658-64. PubMed ID: 26387577
    [Abstract] [Full Text] [Related]

  • 18. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.
    Dtsch Med Wochenschr; 2010 Mar 01; 135(9):385-9. PubMed ID: 20180162
    [Abstract] [Full Text] [Related]

  • 19. Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer.
    Lin WT, Wen YW, Chien CR, Gau CS, Chiang SC, Hsiao FY.
    Clin Ther; 2014 Sep 01; 36(9):1287-94. PubMed ID: 25130388
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.